COVID-19 vaccines Safety data Main navigation COVID-19 vaccines Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Moderna COVID-19 vaccine AstraZeneca COVID-19 vaccine Novavax COVID-19 vaccine Influenza vaccines National Immunisation Program Schedule vaccines AusVaxSafety is conducting active vaccine safety surveillance of the COVID-19 vaccines in use in Australia to ensure their ongoing safety. The COVID-19 vaccines currently being used are Comirnaty (Pfizer), Vaxzevria (AstraZeneca), Spikevax (Moderna) and Nuvaxovid (Novavax). AusVaxSafety is currently reporting safety data on Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. AusVaxSafety moving to fortnightly reporting of COVID-19 vaccine safety data AusVaxSafety has been reporting COVID-19 vaccine safety surveillance data weekly since the vaccination program commenced on 22 February 2021. More than 2.5 million Australians have participated in this surveillance, by completing more than 6.3 million safety surveys, outlining their experience following their COVID-19 vaccination. As a result of this high level of participation, we now have an unprecedented amount of safety data, specific to Australia, on short-term adverse events following vaccination (AEFI). To date, the AEFI data reported are consistent with those seen in clinical trials and surveillance in other countries, reaffirming the safety of COVID-19 vaccines in use in Australia. The safety data received from the 6.3 million survey responses have remained very stable over this time, with minimal change to the safety profile of the vaccines. As a result, AusVaxSafety will now be updating COVID-19 vaccine safety data on a fortnightly basis, instead of weekly, on this page. The next update will occur on Wednesday 18 May 2022. The AusVaxSafety team will continue to regularly review data received on an ongoing basis to ensure there are no new safety concerns. Latest COVID-19 vaccine safety data Click on the tiles below to view AusVaxSafety COVID-19 vaccine safety data for specific population groups. Pfizer COVID-19 vaccine adult formulation View the latest safety data for Pfizer COVID-19 vaccine adult formulation here Pfizer COVID-19 vaccine paediatric formulation (5-11 years) View the latest safety data for Pfizer COVID-19 vaccine paediatric formulation (5-11 years) here Moderna COVID-19 vaccine View the latest Moderna COVID-19 vaccine safety data here AstraZeneca COVID-19 vaccine View the latest AstraZeneca COVID-19 vaccine safety data here Novavax COVID-19 vaccine View the latest Novavax COVID-19 vaccine safety data here Safety data Main navigation COVID-19 vaccines Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Moderna COVID-19 vaccine AstraZeneca COVID-19 vaccine Novavax COVID-19 vaccine Influenza vaccines National Immunisation Program Schedule vaccines News & events All news & events 31 March 2022 | News AusVaxSafety commences routine monitoring of 2022 seasonal influenza vaccines 17 March 2022 | News Children experience fewer side effects from COVID-19 vaccine 27 February 2022 | News AusVaxSafety actively monitoring Novavax COVID-19 vaccine safety 23 February 2022 | News Do COVID boosters cause more or fewer side effects? How quickly does protection wane? Your questions answered